WO2003024481A3 - Packaging of immunostimulatory substances into virus-like particles: method of preparation and use - Google Patents

Packaging of immunostimulatory substances into virus-like particles: method of preparation and use Download PDF

Info

Publication number
WO2003024481A3
WO2003024481A3 PCT/IB2002/004132 IB0204132W WO03024481A3 WO 2003024481 A3 WO2003024481 A3 WO 2003024481A3 IB 0204132 W IB0204132 W IB 0204132W WO 03024481 A3 WO03024481 A3 WO 03024481A3
Authority
WO
WIPO (PCT)
Prior art keywords
vlps
cpg
antigens
virus
particles
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2002/004132
Other languages
French (fr)
Other versions
WO2003024481A2 (en
Inventor
Martin F Bachmann
Tazio Storni
Patrick Maurer
Alain Tissot
Katrin Schwarz
Edwin Meijerink
Gerad Lipowsky
Paul Pumpens
Indulis Cielens
Regina Renhofa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cytos Biotechnology AG
Original Assignee
Cytos Biotechnology AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to JP2003528575A priority Critical patent/JP4516748B2/en
Priority to AU2002339224A priority patent/AU2002339224B2/en
Priority to AT02777600T priority patent/ATE447967T1/en
Priority to HK04110189.6A priority patent/HK1067058B/en
Priority to CA2492826A priority patent/CA2492826C/en
Priority to CN028179358A priority patent/CN1599623B/en
Priority to DK02777600.4T priority patent/DK1450856T3/en
Priority to EP02777600A priority patent/EP1450856B1/en
Application filed by Cytos Biotechnology AG filed Critical Cytos Biotechnology AG
Priority to DE60234375T priority patent/DE60234375D1/en
Publication of WO2003024481A2 publication Critical patent/WO2003024481A2/en
Anticipated expiration legal-status Critical
Publication of WO2003024481A3 publication Critical patent/WO2003024481A3/en
Priority to AU2009200115A priority patent/AU2009200115B2/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103—Receptors for growth factors
    • A61K39/001104—Epidermal growth factor receptors [EGFR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103—Receptors for growth factors
    • A61K39/001106—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001129—Molecules with a "CD" designation not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001148—Regulators of development
    • A61K39/00115—Apoptosis related proteins, e.g. survivin or livin
    • A61K39/001151—Apoptosis related proteins, e.g. survivin or livin p53
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • A61K39/001156—Tyrosinase and tyrosinase related proteinases [TRP-1 or TRP-2]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001169—Tumor associated carbohydrates
    • A61K39/001171—Gangliosides, e.g. GM2, GD2 or GD3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00118—Cancer antigens from embryonic or fetal origin
    • A61K39/001182—Carcinoembryonic antigen [CEA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/001186—MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00119—Melanoma antigens
    • A61K39/001191—Melan-A/MART
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00119—Melanoma antigens
    • A61K39/001192—Glycoprotein 100 [Gp100]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/04—Amoebicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6075—Viral proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/22011—Polyomaviridae, e.g. polyoma, SV40, JC
    • C12N2710/22022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/22011—Polyomaviridae, e.g. polyoma, SV40, JC
    • C12N2710/22023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10123—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/00034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/18011—Details ssRNA Bacteriophages positive-sense
    • C12N2795/18111—Leviviridae
    • C12N2795/18122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Pulmonology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Developmental Biology & Embryology (AREA)
  • Reproductive Health (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Dermatology (AREA)
  • General Engineering & Computer Science (AREA)

Abstract

The invention relates to the finding that virus like particles (VLPs) can be loaded with immunostimulatory substances, in particular with DNA oligonucleotides containing non-methylated C and G (CpGs). Such CpG- VLPs are dramatically more immunogenic than their CpG-free counterparts and induce enhanced B and T cell responses. The immune response against antigens optionally coupled, fused or attached otherwise to the VLPs is similarly enhanced as the immune response against the VLP itself. In addition, the T cell responses against both the VLPs and antigens are especially directed to the Thl type. Antigens attached to CpG-loaded VLPs may therefore be ...∩ ideal vaccines for prophylactic or therapeutic vaccination against allergies, tumors and other self-molecules and chronic viral diseases.
PCT/IB2002/004132 2001-09-14 2002-09-16 Packaging of immunostimulatory substances into virus-like particles: method of preparation and use Ceased WO2003024481A2 (en)

Priority Applications (10)

Application Number Priority Date Filing Date Title
DK02777600.4T DK1450856T3 (en) 2001-09-14 2002-09-16 Packaging of Immunostimulatory CpG in Virus-Like Particles, Method and Use
AT02777600T ATE447967T1 (en) 2001-09-14 2002-09-16 PACKAGING OF IMMUNO-STIMULATIVE CPG IN VIRUS-LIKE PARTICLES: PRODUCTION METHOD AND USE
HK04110189.6A HK1067058B (en) 2001-09-14 2002-09-16 Packaging of immunostimulatory cpg into virus-like particles: method of preparation and use
CA2492826A CA2492826C (en) 2001-09-14 2002-09-16 Encapsulation of unmethylated cpg-containing oligonucleotides into virus-like particles: method of preparation and use
CN028179358A CN1599623B (en) 2001-09-14 2002-09-16 Packaging of immunostimulatory substances into virus-like particles: method of preparation and use
JP2003528575A JP4516748B2 (en) 2001-09-14 2002-09-16 Packaging immunostimulatory substances in virus-like particles: preparation and use
AU2002339224A AU2002339224B2 (en) 2001-09-14 2002-09-16 Packaging of immunostimulatory substances into virus-like particles: method of preparation and use
EP02777600A EP1450856B1 (en) 2001-09-14 2002-09-16 Packaging of immunostimulatory cpg into virus-like particles: method of preparation and use
DE60234375T DE60234375D1 (en) 2001-09-14 2002-09-16 PACKAGING IMMUNSTIMULATING CpG IN VIRUS LIKE PARTICLES: PREPARATION METHOD AND USE
AU2009200115A AU2009200115B2 (en) 2001-09-14 2009-01-09 Packaging of immunostimulatory substances into virus-like particles: method of preparation and use

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US31899401P 2001-09-14 2001-09-14
US60/318,994 2001-09-14
US37414502P 2002-04-22 2002-04-22
US60/374,145 2002-04-22

Publications (2)

Publication Number Publication Date
WO2003024481A2 WO2003024481A2 (en) 2003-03-27
WO2003024481A3 true WO2003024481A3 (en) 2004-06-03

Family

ID=26981773

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2002/004132 Ceased WO2003024481A2 (en) 2001-09-14 2002-09-16 Packaging of immunostimulatory substances into virus-like particles: method of preparation and use

Country Status (12)

Country Link
US (3) US20030099668A1 (en)
EP (2) EP1450856B1 (en)
JP (2) JP4516748B2 (en)
CN (1) CN1599623B (en)
AT (1) ATE447967T1 (en)
AU (2) AU2002339224B2 (en)
CA (1) CA2492826C (en)
CY (1) CY1110585T1 (en)
DE (1) DE60234375D1 (en)
DK (1) DK1450856T3 (en)
ES (1) ES2335979T3 (en)
WO (1) WO2003024481A2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7718623B2 (en) 2004-02-27 2010-05-18 Emori & Co., Ltd. Immunostimulatory oligonucleotide that induces interferon alpha
US9404126B2 (en) 2006-06-12 2016-08-02 Kuros Biosciences Ag Processes for packaging aggregated oligonucleotides into virus-like particles of RNA bacteriophages

Families Citing this family (209)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6572862B1 (en) * 1989-11-08 2003-06-03 Baylor College Of Medicine Methods and reagents to detect and characterize Norwalk and related viruses
US20030232055A1 (en) * 2000-07-31 2003-12-18 Ruslan Medzhitov Innate immune system-directed vaccines
US20030175287A1 (en) * 2001-01-03 2003-09-18 Yale University Innate immune system-directed vaccines
US7320793B2 (en) * 2001-01-19 2008-01-22 Cytos Biotechnology Ag Molecular antigen array
EP1450856B1 (en) 2001-09-14 2009-11-11 Cytos Biotechnology AG Packaging of immunostimulatory cpg into virus-like particles: method of preparation and use
CA2492823A1 (en) * 2001-09-14 2003-03-27 Cytos Biotechnology Ag In vivo activation of antigen presenting cells for enhancement of immune responses induced by virus like particles
US7682618B2 (en) * 2001-11-07 2010-03-23 The United States Of America As Represented By The Secretary Of The Army Generation of virus-like particles and use as panfilovirus vaccine
CA2466982A1 (en) * 2001-11-19 2003-05-30 Becton, Dickinson And Company Pharmaceutical compositions in particulate form
AU2003219383B2 (en) 2002-04-22 2010-08-26 Bioniche Life Sciences Inc. Oligonucleotide compositions and their use for the modulation of immune responses
CA2486118A1 (en) * 2002-06-07 2003-12-18 Large Scale Biology Corporation Flexible vaccine assembly and vaccine delivery platform
BR0311995A (en) * 2002-06-20 2005-04-05 Cytos Biotechnology Ag Virus-like particles packaged for use as adjuvants: Method of preparation and use
WO2004003143A2 (en) * 2002-06-26 2004-01-08 Advanced Bionutrition Corporation Viruses and virus-like particles for multiple antigen and target display
JP4726483B2 (en) 2002-07-17 2011-07-20 サイトス バイオテクノロジー アーゲー Molecular antigen array
DE60336902D1 (en) * 2002-07-19 2011-06-09 Cytos Biotechnology Ag VACCINE COMPOSITIONS CONTAINING AMYLOID BETA 1-6 ANTIGENARRAYS
MXPA04011247A (en) * 2002-07-19 2005-02-17 Cytos Biotechnology Ag GRELINA CARRIER CONJUGATES.
AU2003296902A1 (en) * 2002-09-03 2004-05-04 Kentucky Bioprocessing, Llc Production of peptides in plants as viral coat protein fusions
EP2301573A1 (en) 2002-10-01 2011-03-30 Novartis Vaccines and Diagnostics, Inc. Anti-cancer and anti-infectious disease compositions and methods for using same
CN1809380B (en) 2002-10-11 2010-05-12 启龙有限公司 Peptide-vaccine for broad protection against highly virulent meningococcal lineages
CA2503693A1 (en) 2002-10-29 2004-05-13 Coley Pharmaceutical Group, Ltd. Use of cpg oligonucleotides in the treatment of hepatitis c virus infection
JP2006512927A (en) 2002-12-11 2006-04-20 コーリー ファーマシューティカル グループ，インコーポレイテッド 5 'CPG nucleic acids and methods of use thereof
ES2461350T3 (en) 2003-01-30 2014-05-19 Novartis Ag Injectable vaccines against multiple serogroups of meningococci
RU2351362C2 (en) * 2003-03-26 2009-04-10 Цитос Байотекнолоджи Аг CONJUGATES OF PEPTIDE Melan-A, VIRUS-LIKE PARTICLE ANALOGUE
US7537767B2 (en) * 2003-03-26 2009-05-26 Cytis Biotechnology Ag Melan-A- carrier conjugates
US20060210588A1 (en) * 2003-03-26 2006-09-21 Cytos Biotechnology Ag Hiv-peptide-carrier-conjugates
EP1623229A2 (en) * 2003-05-15 2006-02-08 Cytos Biotechnology AG Selection of b cells with specificity of interest: method of preparation and use
US7790189B2 (en) * 2003-05-15 2010-09-07 Mitsui Sugar Co., Ltd. Immunostimulating agents
EP1644034B1 (en) * 2003-07-10 2011-01-12 Cytos Biotechnology AG Composition for enhancing an immune response comprising packaged virus-like particles
CA2544240A1 (en) * 2003-07-22 2005-02-17 Cytos Biotechnology Ag Cpg-packaged liposomes
US7320795B2 (en) * 2003-07-30 2008-01-22 Vaccine Research Institute Of San Diego Rodent hepatitis B virus core proteins as vaccine platforms and methods of use thereof
US7144712B2 (en) * 2003-07-30 2006-12-05 Vaccine Research Institute Of San Diego Human hepatitis B virus core proteins as vaccine platforms and methods of use thereof
CA2534060C (en) 2003-07-30 2012-06-12 Vaccine Research Institute Of San Diego Hepatitis virus core proteins as vaccine platforms and methods of use thereof
NZ546430A (en) 2003-10-02 2009-04-30 Novartis Vaccines & Diagnostic Liquid vaccines for multiple meningococcal serogroups
GB0323103D0 (en) 2003-10-02 2003-11-05 Chiron Srl De-acetylated saccharides
EP1758925A4 (en) * 2003-12-01 2009-04-08 Dow Global Technologies Inc Recombinant icosahedral virus like particle production in pseudomonads
CN1905903A (en) * 2004-01-20 2007-01-31 赛托斯生物技术公司 Ghrelin-carrier conjugates
DE202005022108U1 (en) 2004-03-09 2013-11-12 Novartis Vaccines And Diagnostics, Inc. Influenza virus vaccines
GB0500787D0 (en) 2005-01-14 2005-02-23 Chiron Srl Integration of meningococcal conjugate vaccination
GB0409745D0 (en) 2004-04-30 2004-06-09 Chiron Srl Compositions including unconjugated carrier proteins
US9402915B2 (en) 2004-04-30 2016-08-02 Glaxosmithkline Biologicals Sa Integration of meningococcal conjugate vaccination
GB0410866D0 (en) 2004-05-14 2004-06-16 Chiron Srl Haemophilius influenzae
ES2647491T3 (en) 2004-05-21 2017-12-21 Novartis Vaccines And Diagnostics, Inc. Alphavirus vectors for influenza virus vaccines
EP1773303A2 (en) * 2004-05-25 2007-04-18 Chimeracore, Inc. Self-assembling nanoparticle drug delivery system
US20060165716A1 (en) 2004-07-29 2006-07-27 Telford John L Immunogenic compositions for gram positive bacteria such as streptococcus agalactiae
AU2005281743A1 (en) * 2004-08-04 2006-03-16 Cytos Biotechnology Ag Carrier conjugates of GnRH-peptides
EP1789566A1 (en) * 2004-09-03 2007-05-30 Consejo Superior De Investigaciones Cientificas Nucleic acid sequences encoding proteins capable of associating into a virus-like particle
MX2007003171A (en) * 2004-09-21 2007-05-23 Cytos Biotechnology Ag Virus-like particles comprising a fusion protein of the coat protein of ap205 and an antigenic polypeptide.
CN101052411B (en) * 2004-10-05 2011-04-06 赛托斯生物技术公司 VLP-antigen conjugates and their uses as vaccines
NZ554388A (en) * 2004-10-05 2010-01-29 Cytos Biotechnology Ag VLP-Antigen conjugates and their uses as vaccines
GB0424092D0 (en) 2004-10-29 2004-12-01 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
US9492400B2 (en) 2004-11-04 2016-11-15 Massachusetts Institute Of Technology Coated controlled release polymer particles as efficient oral delivery vehicles for biopharmaceuticals
RU2007126553A (en) * 2004-12-13 2009-01-20 Цитос Биотехнологи Аг (Ch) ORDERED SERIES OF IL-15 ANTIGENES AND THEIR APPLICATION
WO2006083706A2 (en) * 2005-01-31 2006-08-10 Vaxinnate Corporation Method to identify polypeptide toll-like receptor (tlr) ligands
GB0502095D0 (en) 2005-02-01 2005-03-09 Chiron Srl Conjugation of streptococcal capsular saccharides
SI2351772T1 (en) 2005-02-18 2016-11-30 Glaxosmithkline Biologicals Sa Proteins and nucleic acids from meningitis/sepsis-associated Escherichia coli
JP2008530245A (en) 2005-02-18 2008-08-07 ノバルティス ヴァクシンズ アンド ダイアグノスティクス， インコーポレイテッド Antigens from uropathogenic strains
PL1868642T3 (en) 2005-03-18 2013-10-31 Cytos Biotechnology Ag Cat allergen fusion proteins and uses thereof
LT5414B (en) * 2005-04-13 2007-04-25 Biotechnologijos Institutas Process for preparing monoclonal antibodies; hybridoma cell lines generated by this process and recombinant chimeric virus-like particles with inserted foreign protein fragments as immunogenes to generate hybridomas by this process
JP2008539252A (en) * 2005-04-25 2008-11-13 スリーエム イノベイティブ プロパティズ カンパニー Immune activation composition
EP1736538A1 (en) 2005-06-21 2006-12-27 Cytos Biotechnology AG Process for the preparative purification of virus-like-particles (VLPs)
ES2310062B1 (en) 2005-07-15 2009-11-13 Bionostra, S.L. PSEUDOVIRAL PARTICLES CHEMICAL EMPTY DERIVED FROM VIRUS CAUSING INFECTIOUS BURSITIS DISEASE (IBDV), PROCEDURE OF OBTAINING AND APPLICATIONS.
US20110027220A1 (en) 2005-09-28 2011-02-03 Cytos Biotechnology Ag Interleukin-1 Conjugates and Uses Thereof
CA2626253A1 (en) 2005-10-18 2007-04-26 Novartis Vaccines And Diagnostics, Inc. Mucosal and systemic immunizations with alphavirus replicon particles
AU2006335256B2 (en) 2005-11-22 2012-10-18 Novartis Vaccines And Diagnostics, Inc. Norovirus and sapovirus antigens
GB0524066D0 (en) 2005-11-25 2006-01-04 Chiron Srl 741 ii
WO2007068747A1 (en) * 2005-12-14 2007-06-21 Cytos Biotechnology Ag Immunostimulatory nucleic acid packaged particles for the treatment of hypersensitivity
WO2007070682A2 (en) * 2005-12-15 2007-06-21 Massachusetts Institute Of Technology System for screening particles
ES2555544T3 (en) 2006-03-07 2016-01-04 Vaxinnate Corporation Compositions that include hemagglutinin, preparation methods and methods of use thereof
WO2007109813A1 (en) 2006-03-23 2007-09-27 Novartis Ag Imidazoquinoxaline compounds as immunomodulators
CA2648099C (en) * 2006-03-31 2012-05-29 The Brigham And Women's Hospital, Inc System for targeted delivery of therapeutic agents
EP2019691B1 (en) 2006-05-15 2020-08-12 Massachusetts Institute of Technology Polymers for functional particles
WO2007137117A2 (en) * 2006-05-17 2007-11-29 Massachusetts Institute Of Technology Aptamer-directed drug delivery
AU2013204383B2 (en) * 2006-06-12 2016-09-22 Kuros Us Llc Processes for packaging oligonucleotides into virus-like particles of RNA bacteriophages
US9381477B2 (en) * 2006-06-23 2016-07-05 Massachusetts Institute Of Technology Microfluidic synthesis of organic nanoparticles
EP2586790A3 (en) 2006-08-16 2013-08-14 Novartis AG Immunogens from uropathogenic Escherichia coli
EP2125854B1 (en) 2006-12-12 2016-10-26 Kuros Biosciences AG Oligonucleotides containing high concentrations of guanine monomers
WO2008071774A1 (en) * 2006-12-14 2008-06-19 Cytos Biotechnology Ag Purification process for coat protein of rna bacteriophages
EP2134830A2 (en) * 2007-02-09 2009-12-23 Massachusetts Institute of Technology Oscillating cell culture bioreactor
WO2008124632A1 (en) * 2007-04-04 2008-10-16 Massachusetts Institute Of Technology Amphiphilic compound assisted nanoparticles for targeted delivery
CA2685308A1 (en) * 2007-04-27 2009-01-29 Dow Global Technologies Inc. Improved production and in vivo assembly of soluble recombinant icosahedral virus-like particles
GB0713880D0 (en) 2007-07-17 2007-08-29 Novartis Ag Conjugate purification
GB0714963D0 (en) 2007-08-01 2007-09-12 Novartis Ag Compositions comprising antigens
CA2699513C (en) 2007-09-12 2018-03-13 Novartis Ag Gas57 mutant antigens and gas57 antibodies
CA2917512C (en) 2007-10-12 2025-08-05 President And Fellows Of Harvard College Vaccine nanotechnology
US20110014231A1 (en) * 2007-11-05 2011-01-20 Mor Research Applications Ltd Anti-measles cancer immunotherapy
GB0818453D0 (en) 2008-10-08 2008-11-12 Novartis Ag Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
BRPI0821240B8 (en) 2007-12-21 2022-10-04 Novartis Ag mutant forms of streptolysin o
EP2886551A3 (en) 2008-02-21 2015-09-23 Novartis AG Meningococcal fhbp polypeptides
AU2009236585B2 (en) 2008-04-18 2013-03-07 Vaxinnate Corporation Deletion mutants of flagellin and methods of use
CN101559224B (en) * 2008-04-18 2012-07-11 北京生物制品研究所 Poliomyelitis vaccine
NO339169B1 (en) * 2008-04-24 2016-11-14 Chemoforma Ltd Functional fish feed comprising peptidoglycan and nucleotides
GB0808780D0 (en) * 2008-05-15 2008-06-18 Big Dna Ltd Fish vaccines
WO2009156960A2 (en) 2008-06-27 2009-12-30 Pfizer Inc. Novel adjuvant compositions
US9296790B2 (en) 2008-10-03 2016-03-29 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods and compositions for protein delivery
US8591905B2 (en) 2008-10-12 2013-11-26 The Brigham And Women's Hospital, Inc. Nicotine immunonanotherapeutics
US8277812B2 (en) 2008-10-12 2012-10-02 Massachusetts Institute Of Technology Immunonanotherapeutics that provide IgG humoral response without T-cell antigen
US8343498B2 (en) 2008-10-12 2013-01-01 Massachusetts Institute Of Technology Adjuvant incorporation in immunonanotherapeutics
US8343497B2 (en) 2008-10-12 2013-01-01 The Brigham And Women's Hospital, Inc. Targeting of antigen presenting cells with immunonanotherapeutics
MX337723B (en) 2008-12-09 2016-03-15 Pfizer Vaccines Llc IgE CH3 PEPTIDE VACCINE.
WO2010067262A1 (en) * 2008-12-09 2010-06-17 Pfizer Inc. Immunostimulatory oligonucleotides
CN102481349B (en) 2009-01-12 2014-10-15 诺华股份有限公司 Cna_B Domain in Vaccines Against Gram-Positive Bacteria
CN102438650A (en) 2009-03-06 2012-05-02 诺华有限公司 Chlamydia antigens
NZ612315A (en) 2009-04-14 2014-10-31 Novartis Ag Compositions for immunising against staphylococcus aureus
WO2010122164A1 (en) 2009-04-23 2010-10-28 Cytos Biotechnology Ag VIRUS-LIKE PARTICLES OF BACTERIOPHAGE φCB5
AU2010243490A1 (en) * 2009-04-30 2011-11-24 Cytos Biotechnology Ag Influenza hemagglutinin compositions and uses thereof
ES2662716T3 (en) 2009-07-07 2018-04-09 Glaxosmithkline Biologicals Sa Preserved immunogens of Escherichia coli
SI2464658T1 (en) 2009-07-16 2015-02-27 Novartis Ag Detoxified escherichia coli immunogens
CA2768346A1 (en) 2009-07-30 2011-02-03 Pfizer Vaccines Llc Antigenic tau peptides and uses thereof
JP2013502918A (en) 2009-08-27 2013-01-31 ノバルティス アーゲー Hybrid polypeptide comprising Neisseria meningitidis fHBP sequence
DK2473605T3 (en) 2009-09-03 2018-05-28 Pfizer Vaccines Llc PCSK9-VACCINE
EP2493510B1 (en) 2009-09-30 2020-07-08 GlaxoSmithKline Biologicals SA Conjugation of staphylococcus aureus type 5 and type 8 capsular polysaccharides
GB0918392D0 (en) 2009-10-20 2009-12-02 Novartis Ag Diagnostic and therapeutic methods
BR112012010531A2 (en) 2009-10-27 2019-09-24 Novartis Ag "fhbp meningococcal modification polypeptides"
GB0919690D0 (en) 2009-11-10 2009-12-23 Guy S And St Thomas S Nhs Foun compositions for immunising against staphylococcus aureus
US9173954B2 (en) 2009-12-30 2015-11-03 Glaxosmithkline Biologicals Sa Polysaccharide immunogens conjugated to E. coli carrier proteins
TWI378144B (en) * 2010-02-09 2012-12-01 Univ Nat Pingtung Sci & Tech Recombinant plasmic containing multicopy cpg motifs and transformant thereof for applying on dna adjuvant in avian vaccines
GB201003333D0 (en) 2010-02-26 2010-04-14 Novartis Ag Immunogenic proteins and compositions
JP6199036B2 (en) * 2010-03-16 2017-09-20 バイオエヌテック アーゲーＢｉｏＮＴｅｃｈ ＡＧ Tumor vaccination involved in humoral immune response to self-protein
GB201005625D0 (en) 2010-04-01 2010-05-19 Novartis Ag Immunogenic proteins and compositions
CA2796314A1 (en) 2010-04-13 2011-10-20 Novartis Ag Benzonapthyridine compositions and uses thereof
CN102933267B (en) 2010-05-28 2015-05-27 泰特里斯在线公司 Interactive hybrid asynchronous computer game infrastructure
EP2942061A3 (en) 2010-06-07 2016-01-13 Pfizer Vaccines LLC Ige ch3 peptide vaccine
GB201009861D0 (en) 2010-06-11 2010-07-21 Novartis Ag OMV vaccines
US9192661B2 (en) 2010-07-06 2015-11-24 Novartis Ag Delivery of self-replicating RNA using biodegradable polymer particles
WO2012031205A2 (en) 2010-09-03 2012-03-08 The Brigham And Women's Hospital, Inc. Lipid-polymer hybrid particles
GB201101665D0 (en) 2011-01-31 2011-03-16 Novartis Ag Immunogenic compositions
WO2012072769A1 (en) 2010-12-01 2012-06-07 Novartis Ag Pneumococcal rrgb epitopes and clade combinations
WO2012085668A2 (en) 2010-12-24 2012-06-28 Novartis Ag Compounds
EP2471926A3 (en) 2010-12-30 2012-07-11 Intervet International BV Immunostimulatory oligodeoxynucleotides
US9238679B2 (en) 2011-02-11 2016-01-19 The Trustees Of The University Of Pennslyvania Nucleic acid molecule encoding hepatitis B virus core protein and surface antigen protein and vaccine comprising the same
EA037377B1 (en) * 2011-02-11 2021-03-22 Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания Vaccine for inducing an immune response against hbv
WO2012131504A1 (en) 2011-03-02 2012-10-04 Pfizer Inc. Pcsk9 vaccine
KR20140056184A (en) 2011-05-13 2014-05-09 고쿠리츠다이가쿠호진 토쿄고교 다이가꾸 Cytotoxic t cell inducer
EP2714907B1 (en) * 2011-05-26 2016-06-15 Intervet International B.V. Immunostimulatory oligodeoxynucleotides
CA2834440A1 (en) * 2011-05-26 2012-11-29 Intervet International B.V. Immunostimulatory oligodeoxynucleotides
EP3854413A1 (en) 2011-07-06 2021-07-28 GlaxoSmithKline Biologicals SA Immunogenic combination compositions and uses thereof
CA2841047A1 (en) 2011-07-06 2013-01-10 Novartis Ag Immunogenic compositions and uses thereof
PT2734544T (en) * 2011-07-18 2021-03-16 Us Health Methods and compositions for inhibiting polyomavirus-associated pathology
GB201114923D0 (en) 2011-08-30 2011-10-12 Novartis Ag Immunogenic proteins and compositions
EP2755994A2 (en) 2011-09-14 2014-07-23 Novartis AG Escherichia coli vaccine combination
EP2788022B1 (en) 2011-12-08 2018-10-31 GlaxoSmithKline Biologicals SA Clostridium difficile toxin-based vaccine
CA2860310C (en) 2011-12-21 2023-03-21 Apse, Llc Processes using vlps with capsids resistant to hydrolases
CN104011080B (en) 2011-12-22 2017-10-20 弗·哈夫曼-拉罗切有限公司 Full-length antibody display system for eukaryotic cells and use thereof
WO2013108272A2 (en) 2012-01-20 2013-07-25 International Centre For Genetic Engineering And Biotechnology Blood stage malaria vaccine
WO2013124473A1 (en) 2012-02-24 2013-08-29 Novartis Ag Pilus proteins and compositions
EP3663395B1 (en) 2012-03-26 2024-07-31 The United States of America, as Represented by The Secretary, Department of Health and Human Services Office of Technology, Transfer, Delivery of packaged rna to mammalian cells
CN108671228A (en) 2012-04-26 2018-10-19 诺华股份有限公司 antigen and antigen combination
US10279026B2 (en) 2012-04-26 2019-05-07 Glaxosmithkline Biologicals Sa Antigens and antigen combinations
RU2014151567A (en) 2012-05-22 2016-07-10 Новартис Аг CONJUGATE MENINGOCOCCA SEROGRAPH X
US20150140068A1 (en) 2012-07-06 2015-05-21 Novartis Ag Immunogenic compositions and uses thereof
US8932598B2 (en) 2012-08-28 2015-01-13 Vaxinnate Corporation Fusion proteins and methods of use
CA2885625A1 (en) 2012-10-02 2014-04-10 Glaxosmithkline Biologicals S.A. Nonlinear saccharide conjugates
AR092896A1 (en) 2012-10-03 2015-05-06 Novartis Ag IMMUNOGENIC COMPOSITIONS
JP2016507520A (en) 2013-01-23 2016-03-10 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー Stabilized hepatitis B core polypeptide
CA2900008C (en) 2013-02-07 2025-10-07 Children's Medical Center Corporation Protein antigens that provide protection against pneumococcal colonization and/or disease
EP2968517A4 (en) * 2013-03-15 2017-02-22 Bullet Biotechnology, Inc. Specific multivalent virus-like particle vaccines and uses thereof
AU2014227748B2 (en) 2013-03-15 2019-02-14 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Compositions and methods for treating fungal and bacterial pathogens
BR112015029559A2 (en) 2013-06-19 2017-12-12 Apse Llc virus-like particle, nucleic acid, and methods for producing double-stranded rna and sirna, shrna, sshrna, 1shrna, and mirna
KR20160042917A (en) 2013-07-25 2016-04-20 엑시큐어, 인크. Spherical nucleic acid-based constructs as immunostimulatory agents for prophylactic and therapeutic use
WO2015024992A2 (en) * 2013-08-22 2015-02-26 Cytos Biotechnology Ag Treatment of asthma
UA121200C2 (en) 2013-09-19 2020-04-27 Зоетіс Сервісіз Ллс OIL-BASED ADJUSTANT
KR102467982B1 (en) 2013-12-16 2022-11-16 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 Cancer immunotherapy by delivering class ii mhc antigens using a vlp-replicon
WO2015123291A1 (en) 2014-02-11 2015-08-20 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Pcsk9 vaccine and methods of using the same
EP3164113B1 (en) 2014-06-04 2019-03-27 Exicure, Inc. Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applications
US11213593B2 (en) 2014-11-21 2022-01-04 Northwestern University Sequence-specific cellular uptake of spherical nucleic acid nanoparticle conjugates
SI3240801T1 (en) 2014-12-31 2021-04-30 Checkmate Pharmaceuticals, Inc. Combined tumor immunotherapy
US10526376B2 (en) 2015-01-15 2020-01-07 University Of Copenhagen Virus-like particle with efficient epitope display
EP4248992A3 (en) 2015-01-16 2023-12-27 Zoetis Services LLC Foot-and-mouth disease vaccine
EP3368068B1 (en) 2015-10-30 2020-11-18 University of Copenhagen Virus like particle with efficient epitope display
US20190046638A1 (en) * 2016-04-01 2019-02-14 Checkmate Pharmaceuticals, Inc. Fc RECEPTOR-MEDIATED DRUG DELIVERY
WO2017184655A1 (en) * 2016-04-18 2017-10-26 University Of Florida Research Foundaiton, Inc. Stable poliovirus variants and uses thereof
AU2017256727B2 (en) 2016-04-27 2022-09-29 Saiba Animal Health Ag Treatment of canine atopic dermatitis
WO2017186808A1 (en) 2016-04-27 2017-11-02 Allergy Therapeutics (Uk) Limited Treatment of peanut allergy
US11364304B2 (en) 2016-08-25 2022-06-21 Northwestern University Crosslinked micellar spherical nucleic acids
BE1025162B9 (en) 2016-12-06 2019-01-07 Glaxosmithkline Biologicals Sa PURIFICATION PROCESS FOR CAPSULAR POLYSACCHARIDES
US10434171B2 (en) 2016-12-23 2019-10-08 United States of America as Represented by Secretary of Agriculture Microfluidized Mycobacterium avium fragments as an adjuvant and carrier for mucosal vaccine delivery
US10566881B2 (en) 2017-01-27 2020-02-18 Franklin Electric Co., Inc. Motor drive system including removable bypass circuit and/or cooling features
US11696954B2 (en) 2017-04-28 2023-07-11 Exicure Operating Company Synthesis of spherical nucleic acids using lipophilic moieties
US12459965B2 (en) 2017-10-09 2025-11-04 Compass Pathfinder Limited Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
EP3752194A4 (en) 2018-02-13 2022-03-16 Checkmate Pharmaceuticals, Inc. ANTI-TUMOR IMMUNOTHERAPY COMPOSITIONS AND METHODS
US11633471B2 (en) 2018-03-06 2023-04-25 Unm Rainforest Innovations Compositions and methods for reducing serum triglycerides
SG11202009647VA (en) 2018-04-09 2020-10-29 Checkmate Pharmaceuticals Packaging oligonucleotides into virus-like particles
JP7366057B2 (en) 2018-04-19 2023-10-20 チェックメイト ファーマシューティカルズ， インコーポレイテッド Synthetic RIG-I-like receptor agonists
EP3835414A4 (en) * 2018-08-07 2022-05-25 Institute Of Biophysics, Chinese Academy Of Sciences CD4+ T LYMPHOCYTE ACTIVATION METHOD
AU2019406749A1 (en) 2018-12-20 2021-05-27 Saiba AG Virus-like particles of CMV modified by fusion
JP2022529781A (en) 2019-04-17 2022-06-24 コンパス パスファインダー リミテッド Treatment of depression and various other disorders with psilocybin
US12161710B2 (en) 2019-07-24 2024-12-10 Unm Rainforest Innovations Malaria immunogen and methods for using same
JP7707161B2 (en) * 2019-10-23 2025-07-14 チェックメイト ファーマシューティカルズ， インコーポレイテッド Synthetic RIG-I-like receptor agonists
CN111166727A (en) * 2019-11-15 2020-05-19 河南省生物工程技术研究中心 Tumor immunotherapy compound and preparation method and application thereof
CN110862435B (en) * 2019-12-05 2021-09-24 中国农业大学 African swine fever CTL epitope polypeptide and its application
CN111214663B (en) * 2020-03-06 2022-03-15 中国人民解放军军事科学院军事医学研究院 TMED2 as a therapeutic target for Ebola virus disease
CN111253494B (en) * 2020-03-10 2022-04-26 天康制药(苏州)有限公司 Fusion protein of pig foot-and-mouth disease virus and pig rotavirus, viroid particle, vaccine and preparation method
CN111281973A (en) * 2020-03-31 2020-06-16 清华大学 Vaccine adjuvant containing TRPV2 agonist and use thereof
CU20200028A7 (en) * 2020-04-20 2021-11-04 Ct Ingenieria Genetica Biotecnologia VIRAL NUCLEOPROTEIN AND FORMULATIONS CONTAINING IT
WO2021252450A1 (en) * 2020-06-08 2021-12-16 Adaptive Phage Therapeutics, Inc. Phage display vaccine for covid-19 using a novel peptide sequence
CA3185429A1 (en) 2020-06-12 2021-12-16 Glaxosmithkline Biologicals Sa Bacterial immunization using nanoparticle vaccine
WO2021260131A1 (en) 2020-06-25 2021-12-30 Saiba AG Virus-like particles of cmv modified by fusion
CN113136372B (en) * 2021-05-28 2023-08-01 广西大学 Construction method of recombinant phage
US12121574B2 (en) * 2021-09-28 2024-10-22 Unm Rainforest Innovations Malaria immunogen and methods for using same
WO2023111826A1 (en) 2021-12-14 2023-06-22 Glaxosmithkline Biologicals Sa Bacterial immunization using qbeta hairpin nanoparticle constructs
EP4486448A1 (en) 2022-03-04 2025-01-08 Reset Pharmaceuticals, Inc. Co-crystals or salts comprising psilocin
WO2024047090A2 (en) 2022-08-30 2024-03-07 Saiba Animal Health Ag Modified virus-like particles of cmv
WO2024049946A1 (en) 2022-08-31 2024-03-07 Unm Rainforest Innovations Compositions targeting apoptosis-associated speck-like protein with caspase activation and recruitment domain (asc) and methods of use
EP4601684A2 (en) * 2022-10-14 2025-08-20 Longhorn Vaccines and Diagnostics, LLC Vaccines and antibodies for the treatment and prevention of microbial infections
WO2024091589A1 (en) * 2022-10-28 2024-05-02 Unm Rainforest Innovations Malaria immunogen and methods for using same
WO2024164006A2 (en) * 2023-02-03 2024-08-08 The Regents Of The University Of California Self-amplifying rna form of a constitutively-active sting protein for enhancing t-cell response to antigenpresenting cells
TW202536171A (en) 2024-03-04 2025-09-16 德商百靈佳殷格翰獸藥股份有限公司 Active vaccination for the treatment of ngf-related disorders
WO2025186317A1 (en) 2024-03-06 2025-09-12 Elanco Us Inc. Veterinary compositions of modified virus-like particles of cmv and canine il-1beta mutein antigens
WO2025242657A1 (en) 2024-05-21 2025-11-27 Shape Biopharmaceuticals Ag Lipopeptide building blocks and aggregates

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998050071A1 (en) * 1997-05-01 1998-11-12 Chiron Corporation Use of virus-like particles as adjuvants
WO2000032227A2 (en) * 1998-11-30 2000-06-08 Cytos Biotechnology Ag Ordered molecular presentation of antigens, method of preparation and use

Family Cites Families (129)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2034118A1 (en) 1970-07-09 1972-01-13 Seinfeld, Hugo, Brendel, Walter, Prof Dr . 8000 München Xenogenic nucleic acids for enhancing antigenicity - of peptides and proteins
US4722840A (en) 1984-09-12 1988-02-02 Chiron Corporation Hybrid particle immunogens
FR2581394B1 (en) 1985-05-02 1988-08-05 Grp Genie Genetique PARTICLES HAVING IMMUNOGENIC PROPERTIES OF THE HBS ANTIGEN AND CARRYING A FOREIGN ANTIGENIC SITE TO THE EPITOPES CARRIED BY THE HBS ANTIGEN, ANIMAL VECTORS AND CELLS FOR THE PRODUCTION OF SUCH PARTICLES AND COMPOSITIONS CONTAINING SUCH PARTICLES FOR THE PRODUCTION
US5374426A (en) 1986-09-03 1994-12-20 University Of Saskatchewan Rotavirus nucleocapsid protein VP6 in vaccine compositions
US4918166A (en) 1987-04-10 1990-04-17 Oxford Gene Systems Limited Particulate hybrid HIV antigens
US5057540A (en) * 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
GB8913737D0 (en) 1989-06-15 1989-08-02 Univ Birmingham A novel anti-allergy treatment
NZ235315A (en) 1989-09-19 1991-09-25 Wellcome Found Chimaeric hepadnavirus core antigen proteins and their construction
ES2284161T3 (en) 1990-01-12 2007-11-01 Amgen Fremont Inc. GENERATION OF XENOGENIC ANTIBODIES.
US5334394A (en) 1990-06-22 1994-08-02 The Regents Of The University Of California Human immunodeficiency virus decoy
EP0468520A3 (en) 1990-07-27 1992-07-01 Mitsui Toatsu Chemicals, Inc. Immunostimulatory remedies containing palindromic dna sequences
WO1992011291A1 (en) 1990-12-20 1992-07-09 Smithkline Beecham Biologicals (S.A.) Vaccines based on hepatitis b surface antigen
GB9101550D0 (en) 1991-01-24 1991-03-06 Mastico Robert A Antigen-presenting chimaeric protein
GB9114003D0 (en) 1991-06-28 1991-08-14 Mastico Robert A Chimaeric protein
GB9213601D0 (en) * 1992-06-26 1992-08-12 Mastico Robert A Protein based delivery system
AU678769B2 (en) 1992-07-27 1997-06-12 Hybridon, Inc. Oligonucleotide alkylphosphonothioates
FR2695563B1 (en) 1992-09-11 1994-12-02 Pasteur Institut Microparticles carrying antigens and their use for the induction of humoral or cellular responses.
DK0732936T3 (en) 1993-12-09 2000-09-04 Heinrich Exner Adjuvant to antigens, method of preparation and use
US6727230B1 (en) * 1994-03-25 2004-04-27 Coley Pharmaceutical Group, Inc. Immune stimulation by phosphorothioate oligonucleotide analogs
WO1995026204A1 (en) 1994-03-25 1995-10-05 Isis Pharmaceuticals, Inc. Immune stimulation by phosphorothioate oligonucleotide analogs
FR2722506B1 (en) 1994-07-13 1996-08-14 Rhone Poulenc Rorer Sa COMPOSITION CONTAINING NUCLEIC ACIDS, PREPARATION AND USES
US6239116B1 (en) * 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6429199B1 (en) * 1994-07-15 2002-08-06 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules for activating dendritic cells
US20030026782A1 (en) 1995-02-07 2003-02-06 Arthur M. Krieg Immunomodulatory oligonucleotides
US6207646B1 (en) * 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US20030050263A1 (en) 1994-07-15 2003-03-13 The University Of Iowa Research Foundation Methods and products for treating HIV infection
WO1996002555A1 (en) 1994-07-15 1996-02-01 The University Of Iowa Research Foundation Immunomodulatory oligonucleotides
US5935821A (en) * 1995-01-17 1999-08-10 Board Of Trustees Of The University Of Kentucky Polynucleotides related to monoclonal antibody 1A7 and use for the treatment of melanoma and small cell carcinoma
WO1996030523A2 (en) 1995-03-31 1996-10-03 Hans Wolf Antigen presentation system based on retrovirus-like particles
US5994315A (en) 1995-06-07 1999-11-30 East Carolina University Low adenosine agent, composition, kit and method for treatment of airway disease
US5780448A (en) 1995-11-07 1998-07-14 Ottawa Civic Hospital Loeb Research DNA-based vaccination of fish
ZA9756B (en) 1996-01-16 1997-07-17 Warner Lambert Co Process for preparing 4,6-disubstituted pyrido[3,4-d]-pyrimidines
PT879056E (en) 1996-01-23 2002-10-31 Ribapharm Inc MODIFICATION OF TH1 / TH2 CYTOKINES EXPRESSION THROUGH RIBAVIRIN IN T ACTIVATED LYMPHOCYTES
CA2244946C (en) 1996-01-30 2010-04-13 The Regents Of The University Of California Gene expression vectors which generate an antigen specific immune response and methods of using the same
GB9621091D0 (en) 1996-10-09 1996-11-27 Fondation Pour Le Perfectionem Attenuated microorganisms strains and their uses
JP4111403B2 (en) 1996-10-11 2008-07-02 ザ リージェンツ オブ ザ ユニバーシティー オブ カリフォルニア Immunostimulatory polynucleotide / immunomodulatory molecule complex
EP0855184A1 (en) 1997-01-23 1998-07-29 Grayson B. Dr. Lipford Pharmaceutical composition comprising a polynucleotide and an antigen especially for vaccination
GB9702021D0 (en) 1997-01-31 1997-03-19 Imperial College Medicaments
WO1998037919A1 (en) 1997-02-28 1998-09-03 University Of Iowa Research Foundation USE OF NUCLEIC ACIDS CONTAINING UNMETHYLATED CpG DINUCLEOTIDE IN THE TREATMENT OF LPS-ASSOCIATED DISORDERS
AU753688B2 (en) 1997-03-10 2002-10-24 Ottawa Civic Loeb Research Institute Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
US6406705B1 (en) * 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
WO1998049195A1 (en) 1997-04-29 1998-11-05 Universiteit Utrecht Corona virus-like particles as tools for vaccination and therapy
AU7690898A (en) 1997-05-20 1998-12-11 Ottawa Civic Hospital Loeb Research Institute Vectors and methods for immunization or therapeutic protocols
WO1998055495A2 (en) 1997-06-06 1998-12-10 Dynavax Technologies Corporation Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof
NZ501752A (en) * 1997-06-23 2000-12-22 Ludwig Inst Cancer Res Isolated nona- and decapeptides which bind to HLA molecules, and the use thereof
WO1999007839A2 (en) 1997-08-05 1999-02-18 Vlaams Interuniversitair Instituut Voor Biotechnologie Immunoprotective influenza antigen and its use in vaccination
US6169175B1 (en) 1997-08-06 2001-01-02 Centers For Disease Control And Prevention Preparation and use of recombinant influenza A virus M2 construct vaccines
DK1009413T3 (en) 1997-09-05 2007-06-11 Univ California Use of immunostimulatory oligonucleotides for the prevention or treatment of asthma
US5989868A (en) 1997-09-12 1999-11-23 The Board Of Regents Of The University Of Oklahoma Fusion protein systems designed to increase soluble cytoplasmic expression of heterologous proteins in esherichia coli
US6171591B1 (en) * 1997-12-08 2001-01-09 Pentamer Pharmaceuticals, Inc. Recombinant nodavirus compositions and methods
ATE249240T1 (en) 1998-02-12 2003-09-15 Immune Complex Corp STRATEGICALLY MODIFIED HEPATITIS B CORE PROTEINS AND THEIR DERIVATIVES
US6218371B1 (en) 1998-04-03 2001-04-17 University Of Iowa Research Foundation Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines
US6541438B1 (en) * 1998-05-01 2003-04-01 The Procter & Gamble Company Laundry detergent and/or fabric care compositions comprising a modified cellulase
US5990085A (en) 1998-05-04 1999-11-23 Michigan State University Inhibin-HBc fusion protein
WO1999058118A2 (en) * 1998-05-14 1999-11-18 Cpg Immunopharmaceuticals Gmbh METHODS FOR REGULATING HEMATOPOIESIS USING CpG-OLIGONUCLEOTIDES
US7157092B1 (en) 1998-06-30 2007-01-02 Om Pharma Acyl pseudodipeptides, preparation method and pharmaceutical compositions containing same
WO2000006588A1 (en) 1998-07-27 2000-02-10 University Of Iowa Research Foundation STEREOISOMERS OF CpG OLIGONUCLEOTIDES AND RELATED METHODS
AU5254799A (en) 1998-08-04 2000-02-28 Dryken Technologies, Inc. Method and system for dynamic data-mining and on-line communication of customized information
EP1104306B1 (en) 1998-08-10 2006-01-11 Antigenics Inc. Compositions of cpg and saponin adjuvants and methods of use thereof
US5962636A (en) * 1998-08-12 1999-10-05 Amgen Canada Inc. Peptides capable of modulating inflammatory heart disease
US6927278B1 (en) * 1998-09-01 2005-08-09 Trustees Of The University Of Pennsylvania Peptide scaffolds for transfer of molecules into eukaryotic cells
EP1108017A2 (en) 1998-09-03 2001-06-20 Coley Pharmaceutical GmbH G-motif oligonucleotides and uses thereof
ATE314095T1 (en) * 1998-10-21 2006-01-15 Us Health VIRUS-LIKE PARTICLES FOR INDUCING AUTOANTIBODIES
MXPA01006491A (en) 1998-12-23 2003-06-06 Thompson Boyce Plant Res Expression of immunogenic hepatitis b surface antigens in transgenic plants.
WO2000039304A2 (en) 1998-12-31 2000-07-06 Chiron Corporation Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
WO2000046365A1 (en) * 1999-02-02 2000-08-10 Biocache Pharmaceuticals, Inc. Advanced antigen presentation platform
WO2000046385A1 (en) 1999-02-03 2000-08-10 The Children's Medical Center Corporation Gene repair involving in vivo excision of targeting dna
WO2000050461A1 (en) 1999-02-25 2000-08-31 Smithkline Beecham Biologicals S.A. Epitopes or mimotopes derived from the c-epsilon-3 or c-epsilon-4 domains of ige, antagonists thereof, and their therapeutic uses
EP2286792A1 (en) * 1999-02-26 2011-02-23 Novartis Vaccines and Diagnostics, Inc. Microemulsions with an adsorbent surface, comprising a microdroplet emulsion
WO2000054803A2 (en) 1999-03-16 2000-09-21 Panacea Pharmaceuticals, Llc Immunostimulatory nucleic acids and antigens
US6977245B2 (en) * 1999-04-12 2005-12-20 The United States Of America As Represented By The Department Of Health And Human Services Oligodeoxynucleotide and its use to induce an immune response
CN1227030C (en) 1999-04-19 2005-11-16 史密丝克莱恩比彻姆生物有限公司 Adjuvant compositions comprising saponins and immunostimulatory oligonucleotides
WO2001000232A2 (en) 1999-06-29 2001-01-04 Smithkline Beecham Biologicals S.A. Use of cpg as an adjuvant for hiv vaccine
US7479285B1 (en) 1999-08-19 2009-01-20 Dynavax Technologies Corporation Methods of modulating an immune response using immunostimulatory sequences and compositions for use therein
AU6801800A (en) 1999-08-30 2001-03-26 Ludwig Institute For Cancer Research Isolated nona and decapeptides which bind to hla molecules, and the use thereof
JP2001151698A (en) * 1999-09-10 2001-06-05 Nichiko Pharmaceutical Co Ltd Influenza vaccine
IL148843A0 (en) * 1999-09-25 2002-09-12 Univ Iowa Res Found Immunostimulatory nucleic acids
US6949520B1 (en) * 1999-09-27 2005-09-27 Coley Pharmaceutical Group, Inc. Methods related to immunostimulatory nucleic acid-induced interferon
NZ517928A (en) 1999-09-27 2004-09-24 Coley Pharm Gmbh Methods related to immunostimulatory nucleic acid-induced interferon
EP1221968B1 (en) * 1999-10-13 2010-01-13 Novartis Vaccines and Diagnostics, Inc. Method of obtaining cellular immune responses from proteins
US7223398B1 (en) 1999-11-15 2007-05-29 Dynavax Technologies Corporation Immunomodulatory compositions containing an immunostimulatory sequence linked to antigen and methods of use thereof
DE60018601D1 (en) * 1999-11-24 2005-04-14 Chiron Corp HBV / HCV virus-like particle
WO2001051083A2 (en) 2000-01-13 2001-07-19 Antigenics Inc. Innate immunity-stimulating compositions of cpg and saponin and methods thereof
US6261326B1 (en) 2000-01-13 2001-07-17 North Carolina State University Method for introducing dyes and other chemicals into a textile treatment system
US20010044416A1 (en) * 2000-01-20 2001-11-22 Mccluskie Michael J. Immunostimulatory nucleic acids for inducing a Th2 immune response
AT409085B (en) * 2000-01-28 2002-05-27 Cistem Biotechnologies Gmbh PHARMACEUTICAL COMPOSITION FOR IMMUNULATING AND PRODUCING VACCINES
AU2001236621B2 (en) 2000-02-01 2006-06-15 Mycenax Biotech Inc. Cd40-binding apc-activating molecules
US7585847B2 (en) * 2000-02-03 2009-09-08 Coley Pharmaceutical Group, Inc. Immunostimulatory nucleic acids for the treatment of asthma and allergy
US6756044B1 (en) 2000-02-09 2004-06-29 Genvec, Inc. Antigenic complexes and methods
AU2001239873A1 (en) * 2000-02-24 2001-09-03 The Board Of Trustees Of The Leland Stanford Junior University Adjuvant treatment by in vivo activation of dendritic cells
WO2001077158A1 (en) 2000-04-07 2001-10-18 University Of Leeds Innovations Limited Hepatitis b core antigen fusion proteins
WO2001085208A2 (en) 2000-05-05 2001-11-15 Cytos Biotechnology Ag Molecular antigen arrays and vaccines
EP1294893B1 (en) 2000-06-22 2006-03-15 UCB Pharma Limited Modification of hepatitis b core antigen
AUPQ912000A0 (en) 2000-07-31 2000-08-24 Crown In The Right Of The Queensland Department Of Health, The Improved virus like particles
US20030138769A1 (en) 2000-08-16 2003-07-24 Birkett Ashley J. Immunogenic HBc chimer particles having enhanced stability
MXPA03002640A (en) 2000-09-28 2003-06-19 Chiron Corp Microparticles for delivery of the heterologous nucleic acids.
HU229642B1 (en) 2000-10-18 2014-03-28 Glaxosmithkline Beecham Biolog S A Vaccines against cancers
WO2002053141A2 (en) 2000-12-14 2002-07-11 Coley Pharmaceutical Group, Inc. Inhibition of angiogenesis by nucleic acids
US7320793B2 (en) 2001-01-19 2008-01-22 Cytos Biotechnology Ag Molecular antigen array
US7128911B2 (en) * 2001-01-19 2006-10-31 Cytos Biotechnology Ag Antigen arrays for treatment of bone disease
US7094409B2 (en) * 2001-01-19 2006-08-22 Cytos Biotechnology Ag Antigen arrays for treatment of allergic eosinophilic diseases
US20030050268A1 (en) * 2001-03-29 2003-03-13 Krieg Arthur M. Immunostimulatory nucleic acid for treatment of non-allergic inflammatory diseases
WO2003040308A2 (en) 2001-07-27 2003-05-15 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of sterically stabilized cationic liposomes to efficiently deliver cpg oligonucleotides in vivo
DE60236806D1 (en) 2001-08-13 2010-08-05 Univ Rochester TRANSCUTANEOUS IMMUNIZATION AGAINST PAPILLOMA VIRUSES WITH VIRUSUAL PAPILLOMA VIRUS PARTICLES
EP1450856B1 (en) 2001-09-14 2009-11-11 Cytos Biotechnology AG Packaging of immunostimulatory cpg into virus-like particles: method of preparation and use
CA2492823A1 (en) * 2001-09-14 2003-03-27 Cytos Biotechnology Ag In vivo activation of antigen presenting cells for enhancement of immune responses induced by virus like particles
US7115266B2 (en) * 2001-10-05 2006-10-03 Cytos Biotechnology Ag Angiotensin peptide-carrier conjugates and uses thereof
ES2321491T3 (en) 2001-10-05 2009-06-08 Cytos Biotechnology Ag CONJUGATES THAT CARRY ANGIOTENSIN PEPTIDE AND USE OF THE SAME.
AU2002346960A1 (en) 2001-10-06 2003-04-22 Merial Limited Methods and compositions for promoting growth and innate immunity in young animals
ES2320638T3 (en) 2001-11-07 2009-05-27 Cytos Biotechnology Ag ORDERED PROVISION OF ANTIGENS IL-5, IL-13 OR EOTASINE, FOR THE TREATMENT OF ALLERGIC DISEASES WITH AN EOSYPHILIC COMPONENT.
BR0213941A (en) 2001-11-07 2004-08-31 Cytos Biotechnology Ag Antigen Arrangements for the Treatment of Bone Disease
TW200303759A (en) 2001-11-27 2003-09-16 Schering Corp Methods for treating cancer
JP3881985B2 (en) 2001-12-04 2007-02-14 株式会社アトック Quartz glass fluid single-hole nozzle and quartz glass fluid multi-hole burner head
WO2003059386A2 (en) 2002-01-18 2003-07-24 Cytos Biotechnology Ag Prion protein carrier-conjugates
US20030219459A1 (en) * 2002-01-18 2003-11-27 Cytos Biotechnology Ag Prion protein carrier-conjugates
BR0311995A (en) 2002-06-20 2005-04-05 Cytos Biotechnology Ag Virus-like particles packaged for use as adjuvants: Method of preparation and use
JP4726483B2 (en) 2002-07-17 2011-07-20 サイトス バイオテクノロジー アーゲー Molecular antigen array
DE60336902D1 (en) 2002-07-19 2011-06-09 Cytos Biotechnology Ag VACCINE COMPOSITIONS CONTAINING AMYLOID BETA 1-6 ANTIGENARRAYS
RU2351362C2 (en) * 2003-03-26 2009-04-10 Цитос Байотекнолоджи Аг CONJUGATES OF PEPTIDE Melan-A, VIRUS-LIKE PARTICLE ANALOGUE
US20060210588A1 (en) * 2003-03-26 2006-09-21 Cytos Biotechnology Ag Hiv-peptide-carrier-conjugates
US7537767B2 (en) * 2003-03-26 2009-05-26 Cytis Biotechnology Ag Melan-A- carrier conjugates
EP1644034B1 (en) * 2003-07-10 2011-01-12 Cytos Biotechnology AG Composition for enhancing an immune response comprising packaged virus-like particles
MX2007003171A (en) * 2004-09-21 2007-05-23 Cytos Biotechnology Ag Virus-like particles comprising a fusion protein of the coat protein of ap205 and an antigenic polypeptide.
CN101052411B (en) 2004-10-05 2011-04-06 赛托斯生物技术公司 VLP-antigen conjugates and their uses as vaccines
PL1868642T3 (en) 2005-03-18 2013-10-31 Cytos Biotechnology Ag Cat allergen fusion proteins and uses thereof
US20110027220A1 (en) 2005-09-28 2011-02-03 Cytos Biotechnology Ag Interleukin-1 Conjugates and Uses Thereof
WO2007068747A1 (en) * 2005-12-14 2007-06-21 Cytos Biotechnology Ag Immunostimulatory nucleic acid packaged particles for the treatment of hypersensitivity
EP2231179A2 (en) 2007-12-20 2010-09-29 Cytos Biotechnology AG Ngf conjugates and uses thereof
CA2721657A1 (en) 2008-04-22 2009-10-29 Cytos Biotechnology Ag Vaccine compositions for the treatment of dengue fever and uses thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998050071A1 (en) * 1997-05-01 1998-11-12 Chiron Corporation Use of virus-like particles as adjuvants
WO2000032227A2 (en) * 1998-11-30 2000-06-08 Cytos Biotechnology Ag Ordered molecular presentation of antigens, method of preparation and use

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
GERBER S ET AL: "Human papillomavirus virus-like particles are efficient oral immunogens when coadministered with Escherichia coli heat-labile enterotoxin mutant R192G or CpG DNA.", JOURNAL OF VIROLOGY. UNITED STATES MAY 2001, vol. 75, no. 10, May 2001 (2001-05-01), pages 4752 - 4760, XP002246338, ISSN: 0022-538X *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7718623B2 (en) 2004-02-27 2010-05-18 Emori & Co., Ltd. Immunostimulatory oligonucleotide that induces interferon alpha
US9404126B2 (en) 2006-06-12 2016-08-02 Kuros Biosciences Ag Processes for packaging aggregated oligonucleotides into virus-like particles of RNA bacteriophages

Also Published As

Publication number Publication date
CN1599623A (en) 2005-03-23
ATE447967T1 (en) 2009-11-15
CN1599623B (en) 2011-05-11
EP2196217A1 (en) 2010-06-16
JP2009197001A (en) 2009-09-03
JP4516748B2 (en) 2010-08-04
US9950055B2 (en) 2018-04-24
AU2002339224B2 (en) 2008-10-09
EP1450856A2 (en) 2004-09-01
US20030099668A1 (en) 2003-05-29
AU2009200115B2 (en) 2012-05-03
CA2492826A1 (en) 2003-03-27
DK1450856T3 (en) 2010-05-31
JP2005517632A (en) 2005-06-16
EP1450856B1 (en) 2009-11-11
AU2009200115A1 (en) 2009-02-05
CA2492826C (en) 2016-12-13
US20150030620A1 (en) 2015-01-29
DE60234375D1 (en) 2009-12-24
US8691209B2 (en) 2014-04-08
CY1110585T1 (en) 2015-04-29
WO2003024481A2 (en) 2003-03-27
US20120301499A1 (en) 2012-11-29
JP4749475B2 (en) 2011-08-17
ES2335979T3 (en) 2010-04-07
HK1067058A1 (en) 2005-04-01

Similar Documents

Publication Publication Date Title
DK1450856T3 (en) Packaging of Immunostimulatory CpG in Virus-Like Particles, Method and Use
WO2004000351A8 (en) Packaged virus-like particles for use as adjuvants: method of preparation and use
WO2004084939A3 (en) Hiv-peptide-carrier-conjugates
WO2001060402A3 (en) Proteosome influenza vaccine
EP1687329B8 (en) Optimized expression of hpv 58 l1 in yeast
WO2005089164A3 (en) Inducing cellular immune responses to human papillomavirus using peptide and nucleic acid compositions
WO2002034205A3 (en) Using heat shock proteins to increase immune response
Strugnell et al. Vaccine antigens
Carter et al. Role of adjuvants in modeling the immune response
EP1246644A4 (en) INDUCTION OF CELLULAR IMMUNE RESPONSES TO HUMAN PAPILLOMA VIRUS USING PEPTIDES AND NUCLEIC ACID COMPOSITIONS
WO2003059381A3 (en) Immunogenic preparations and vaccines on the basis of mrna
DE602004031017D1 (en) COMPOSITION PACKAGED VIRUSIC PARTICLES INCLUDING THE IMPROVEMENT OF AN IMMUNE RESPONSE
AU2003246373A1 (en) Recombinant measles viruses expressing epitopes pf antigens of rna viruses and use of the recombinant viruses for the preparation of vaccine compositions
CA2434000A1 (en) Adjuvant viral particle
WO2007008918A3 (en) Virus vaccines comprising envelope-bound immunomodulatory proteins and methods of use thereof
WO2008034388A8 (en) Virus-like particles of capsid proteins from human papillomavirus type 16/58/18/6/11 and the method for preparation and the uses thereof
WO2003089584A3 (en) Use of parapox b2l protein to modify immune responses to administered antigens
WO2002022687A3 (en) Viral chemokine-tumur antigen fusion proteins
WO2011100234A3 (en) Immunogenic hpv l2-containing vlps and related compositions, constructs, and therapeutic methods
NZ516725A (en) Use of modified HPV as a carrier for vaccine against cancer or viral infection of human papillomavirus
WO2004054508A3 (en) Immunogenic compositions including rough phenotype brucella host strains and complementation dna fragments
EP1593738A4 (en) Virus-like particle vaccine containing dengue virus recombinant replicon as its carrier
WO2004045641A3 (en) Antigen-complexes
WO2003094829A3 (en) Pathogen vaccines and methods for using the same
WO2002070004A3 (en) Papillomavirus vaccines

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR LC LK LR LS LT LU LV MA MD MG MN MW MX MZ NO NZ OM PH PL PT RU SD SE SG SI SK SL TJ TM TN TR TZ UA UG US UZ VC VN YU ZA ZM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2002777600

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2492826

Country of ref document: CA

Ref document number: 20028179358

Country of ref document: CN

Ref document number: 2002339224

Country of ref document: AU

Ref document number: 551/CHENP/2004

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2003528575

Country of ref document: JP

WWP Wipo information: published in national office

Ref document number: 2002777600

Country of ref document: EP

DPE2 Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)